北京市71家基层医疗机构2010-2012年HMG-CoA还原酶抑制剂应用情况分析

Utilization of HMG-CoA reductase inhibitors in 71 primary medical institutions in Beijing from 2010 to 2012

目的:调查北京市71家基层医疗机构2010-2012年羟甲基戊二酸单酰辅酶A(HMG-CoA)还原酶抑制剂的应用情况。方法:对北京市71家基层医疗机构在2010-2012年HMG-CoA还原酶抑制剂的应用情况进行统计,包括药品名称、生产厂家、医院归属地和级别。结果:各种HMG-CoA还原酶抑制剂的用量和用药金额均呈逐年上升的趋势。阿托伐他汀和辛伐他汀占据垄断地位,两者的用药金额占HMG-CoA还原酶抑制剂总用药金额的约90%份额。一级医院HMG-CoA还原酶抑制剂的院均用药量和用药金额均明显低于二级医院,郊区医院明显高于市区医院。结论:北京市基层医疗机构使用的HMG-CoA还原酶抑制剂以阿托伐他汀和辛伐他汀为主,外资企业所产药品的用药金额高于内资企业。

Objective： To investigate the utilization of β-hydroxy-β-methyl-glutaryl coenzyme A （HMG-CoA） reductase inhibitors in 71 primary medical institutions in Beijing from 2010 to 2012. Methods： Analysis was made on the utilization of HMG-CoA reductase inhihitors in 71 primary medical institutions in Beijing from 2010 to 2012 ,including drug names,manufacturers,hospital locations and levels. Results：The consumption quantity and consumption sum of various HMG-CoA reductase inhibitors showed a rising trend year by year. Atorvastatin and simvastatin were two predominant lipid-regulating drugs and their consumption sum accounted for about 90% of the total consumption sum. The quantity and consumption sum of HMG-CoA reductase inhibitors in the first-level hospitals were both significantly lower than those of the second-level hospitals, and corresponding data of suburban hospitals were significantly higher than those of urban hospitals. Conclusion： The most frequently used HMG-CoA reductase inhibitors were atorvastatin and simvastatin in primary medical institutions in Beijing. The consumption sum of drugs by foreign enterprises is higher than that of the drugs by domestic enterprises.